Important safety considerations include the risk of pancreatitis (seek medical attention for severe abdominal pain), gallbladder disease, acute kidney injury with dehydration, and potential effects on diabetic retinopathy
An O-glycosylated peptide having multiple forms
Maintenance medications, such as those that treat high cholesterol, mental health or hypertension, are taken long term
Weeks 1-4 Starting dose Weeks 5-8 First increase Weeks 9-12 Therapeutic level Weeks 13-16 Near target Week 17+ Full dose Side Effects & Safety Most side effects are temporary and manageable
Most patients experience improvement as their bodies adjust to the medication over 48 weeks, though some individuals may have persistent symptoms requiring intervention
Each component of the GLOW Blend contributes unique biological activities that fill specific regenerative niches while amplifying the effects of companion peptides